We established Roquefort Therapeutics plc to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. The investment strategy of the Company is to provide Shareholders with an attractive total return achieved primarily through capital appreciation. The Directors believe that there are numerous investment opportunities within both private and public businesses in the medical biotech sector in the United Kingdom, Continental Europe and Australia.
|Non-Executive Director:||Simon Sinclair, Jean Duvall, Dr Darrin Disley|
|Executive Chairman:||Stephen Paul West|
|Chief Executive Officer :||Trevor Ajanthan (Ajan) Reginald|
|Independent Non-Executive Director:||Michael Stein|
|Chief Scientific Officer:||Professor Sir Martin Evans|
|Address:||Eccleston Yards, 25 Eccleston Place, London, United Kingdom|
|Phone:||+44 (0)20 3290 9339|